Latest News

Li Auto (LI) is leaning hard into AI driven products, from its sell out Livis smart glasses launch to new in house models for smart driving and robotics, reshaping how some investors frame the stock. See our latest analysis for Li Auto. Despite the AI push and new financing offers, Li Auto’s recent share price performance has been weak, with a 30 day share price return of 7.36% decline and a 90 day share price return of 29.24% decline. The 1 year total shareholder return of 30.46% decline and...

Healthpeak Properties Inc., a long-established healthcare real estate owner and operator, has drawn fresh attention after underwhelming third-quarter results were followed by renewed interest in its life sciences, medical office, and senior housing portfolio. Investors appear focused on the company’s 36-year dividend record, current income profile, and potential benefits from growing demand for senior housing across the US. We will now examine how Healthpeak Properties’ income track record...

What Ionis’ latest update means for shareholders Ionis Pharmaceuticals (IONS) kicked off 2026 by spotlighting 2025 milestones, including US$105 million in preliminary TRYNGOLZA net sales and progress across several late stage RNA therapies with key regulatory and clinical updates ahead. For you as a shareholder or potential investor, this kind of multi program update matters because it links current commercial performance with a set of upcoming decision points that could influence Ionis'...

Share buy-back puts SpareBank 1 Sør-Norge (OB:SB1NO) in focus SpareBank 1 Sør-Norge (OB:SB1NO) has attracted fresh attention after continuing its share buy-back programme, purchasing 305,000 shares in week 3 of 2026 as part of a planned repurchase of up to 1.0% of its share capital. With 1,281,013 shares now acquired under the programme, equal to 0.34% of issued shares, investors are weighing what this renewed buying activity might suggest about management’s capital priorities and the stock’s...

Morgan Stanley’s downgrade of American Assets Trust (AAT) to Underweight, tied to weak growth concerns, large lease expirations, and a possible 2027 dividend reduction, has quickly become the focal point for investors. See our latest analysis for American Assets Trust. At a share price of $18.06, American Assets Trust has experienced pressure over time, with a 90 day share price return of 10.19% and a 1 year total shareholder return of 23.04%, pointing to fading momentum as recent news,...

Upcoming earnings put JetBlue back in the spotlight JetBlue Airways (JBLU) is back on investors’ radar as it heads into its fourth quarter 2025 earnings report on January 27, 2026, with expectations calling for a wider loss despite modest revenue growth. See our latest analysis for JetBlue Airways. At a share price of $5.16, JetBlue has had a mixed year, with an 11.69% 3 month share price return and a 7.50% 1 month share price return sitting against a 35.18% 1 year total shareholder return...

Gold Resource Corporation reported a past fourth‑quarter 2025 operational turnaround at its Don David Gold Mine, with higher‑grade ore from the Three Sisters area driving record silver sales and a shift toward silver‑weighted production. This operational improvement marks a meaningful change in the company’s revenue mix, increasing its exposure to silver‑linked performance at the Don David operation. We’ll now look at how this operational turnaround and Three Sisters’ higher‑grade ore shape...

First American Financial (FAF) is back in focus after its title insurance subsidiary rolled out a free property title monitoring and fraud alert service for eligible customers, directly targeting rising concerns around real estate fraud. See our latest analysis for First American Financial. The share price is at US$61.30, and recent moves have been mixed, with a 3.23% 7 day share price return set against a 2.68% 30 day share price decline. The 1 year total shareholder return of 1.56% and 5...

Hasbro, Inc. recently appointed Doug Bowser, former President and Chief Operating Officer of Nintendo of America, and Carla Vernón, Chief Executive Officer of The Honest Company, to its Board of Directors, while also scheduling the release of its fourth-quarter and full-year 2025 results for February 10, 2026. The combination of gaming leadership experience and consumer-brand transformation expertise on the new Board, alongside heightened expectations for upcoming earnings, is drawing...

When you see that almost half of the companies in the Infrastructure industry in Australia have price-to-sales ratios...

Why AXT stock is back in focus after a rating change AXT (AXTI) is back on investors’ radar after Needham analyst Charles Shi cut the stock to a hold rating, a shift that appears to be influencing sentiment and recent price swings. See our latest analysis for AXT. While the downgrade and recent volatility, including the share price pullback earlier in January, have cooled near term sentiment, AXT’s recent momentum is still striking. It has a 30 day share price return of 46.14%, a 90 day share...

Earlier in January, Molson Coors Beverage reported adjusted earnings that exceeded Wall Street expectations but reduced its full-year earnings outlook, citing economic pressures and aluminum tariffs. This mix of better-than-expected quarterly results and a more cautious earnings outlook has prompted analysts and investors to reassess the company’s prospects. Next, we’ll examine how this lowered full-year earnings outlook influences Molson Coors’ investment narrative and what it may mean for...

Mongolian Mining Corporation released unaudited operational results for the quarter ended 31 December 2025, reporting higher run-of-mine coal output and increased washed coking coal production versus a year earlier. The company also reported full-year growth in washed coking coal sales volumes and continued to advance its copper-silver-gold project pipeline in Mongolia, underscoring a broader resource portfolio. We will now examine how higher washed coking coal sales and progress in...

Why Structure Therapeutics (GPCR) Is Back on Investors’ Radar Structure Therapeutics (GPCR) is drawing fresh attention after recent analyst commentary pointed to growing confidence in its obesity pipeline, including key trial progress for aleniglipron and a new licensing deal with Genentech. The agreement with Genentech includes a US$100 million upfront payment and potential royalties, while analysts are watching upcoming clinical milestones such as the 44 week ACCESS II readout and a planned...

In recent days, CoreCivic has attracted heightened investor interest following speculation that it may secure a new government contract with the Naval Supply Systems Command. This potential agreement is drawing attention because it could reinforce CoreCivic’s role as a key private provider of services to U.S. government agencies, even amid mixed financial signals and risk considerations. Next, we’ll examine how speculation around the Naval Supply Systems Command contract shapes CoreCivic’s...

Why China Yuchai International (CYD) is on investors’ radar China Yuchai International (CYD) has caught attention after a strong share price move over the past month, prompting investors to reassess how its engine manufacturing and hospitality businesses line up with current expectations. See our latest analysis for China Yuchai International. At a share price of $43.94, China Yuchai International has had a strong run, with a 30 day share price return of 21.15% and a very large 1 year total...

LKQ Corporation recently reported a Q3 2025 earnings beat and raised its 2025 adjusted EPS guidance to a range of US$3 to US$3.15, even as analysts now expect a year-on-year earnings decline for Q4 2025. This combination of stronger-than-expected recent performance and higher full-year guidance, set against forecasts for softer Q4 results, has sharpened investor focus on the company’s earnings quality and outlook. We’ll now look at how LKQ’s raised 2025 adjusted EPS guidance shapes its...

MBX Biosciences (MBX) is back on investor watchlists after Guggenheim issued a series of supportive research updates, highlighting the company’s obesity drug pipeline and upcoming clinical milestones as key factors to monitor. See our latest analysis for MBX Biosciences. The latest Guggenheim commentary arrives after a sharp move in MBX Biosciences’ shares, with a 1 day share price return of 6.44% and a 90 day share price return of 191.88%. The 1 year total shareholder return of 321.70%...

What the ANA partnership means for OUTFRONT Media OUTFRONT Media (OUT) has joined the Association of National Advertisers as a 2026 Strategic Partner, becoming the first out of home media company in the program and securing a seat at key brand marketing forums. For you as an investor, this is less about a single contract and more about access. The company is positioning itself directly in front of senior marketers who control large advertising budgets, while showcasing its in real life media...

Amplifon has launched “The Special Test Rooms,” a global campaign using candid camera footage of real customers reacting to its new invisible hearing device, initially in Italy and then across Europe, the United States, and Australia. By spotlighting the emotional impact of better hearing and authentic user experiences, the campaign reinforces Amplifon’s positioning at the intersection of hearing technology and quality-of-life improvement. We’ll now examine how this focus on real customer...

Recent performance snapshot for W. P. Carey (WPC) With no single headline event driving attention, W. P. Carey (WPC) is drawing interest as investors weigh its recent share performance, income profile, and valuation signals across the past year. See our latest analysis for W. P. Carey. At a share price of $69.93, W. P. Carey has seen a 30 day share price return of 8.22%, while its 1 year total shareholder return of 30.09% points to momentum that has been building rather than fading. If you...

What recent performance says about TransMedics Group (TMDX) With no single headline event driving attention today, TransMedics Group (TMDX) has still attracted interest after a mixed short term stretch and strong longer term returns that stand out among healthcare names. The stock is roughly flat over the past week after a 1% decline in the last session, yet it has returned about 11% over the past month and around 19% in the past 3 months. Longer horizons look very different, with year to...

Contract win in South Korea puts Andritz’s hydropower capabilities in focus Andritz (WBAG:ANDR) has secured a contract to supply equipment and services for a 500-MW pumped storage hydropower plant in South Korea, drawing fresh attention to its role in renewable energy infrastructure in Asia. See our latest analysis for Andritz. The South Korean hydropower contract arrives after a period of firm share price momentum, with Andritz’s latest share price at €70.25 and a 30 day share price return...

Heineken Holding share buyback programme update Heineken Holding (ENXTAM:HEIO) has continued executing the first tranche of its share buyback programme, repurchasing shares on exchange as part of a planned capital return of up to approximately €750 million. See our latest analysis for Heineken Holding. The ongoing buyback comes during a softer patch for the shares, with a 7 day share price return of 2.5% and a year to date share price return of 2.6%. The 1 year total shareholder return of...